Xiong Zhang

Xiong Zhang


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

4 February 2011 in Brain Research
Verified
Journal Article
Closed access
RXRenshi Xu
Renshi Xu
CWChengsi Wu
Chengsi Wu
XZXiong Zhang
Xiong Zhang
QZQiong Zhang
Qiong Zhang
YYYunzhu Yang
Yunzhu Yang
YTYuhui Tao
Yuhui Tao

26 July 2022 in Frontiers in Neurology
Verified
Journal Article
Open access
DLDongcheng Li
Dongcheng Li
TRTengzhu Ren
Tengzhu Ren
HLHao Li
Hao Li
GLGeng Liao
Geng Liao
XZXiong Zhang
Xiong Zhang
Cognitive impairment (CI) is a common complication of Parkinson's disease (PD). The major features of Parkinson's disease with cognitive impairment (PD-CI) include convergence of α-Synuclein (α-Syn) and Alzheimer's disease (AD)-like pathologies, neuroinflammation, and dysbiosis of gut microbiota. Porphyromonas gingivalis (P. gingivalis) is an important pathogen in periodontitis. Recent research has suggested a role of P. gingivalis and its virulence factor in the pathogenesis of PD and AD, in particular concerning neuroinflammation and deposition of α-Synuclein (α-Syn) and amyloid-β (Aβ). Furthermore, in animal models, oral P. gingivalis could cause neurodegeneration through regulating the gut-brain axis, suggesting an oral-gut-brain axis might exist. In this article, we discussed the pathological characteristics of PD-CI and the role of P. gingivalis in them.

27 March 2024 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
DLDongcheng Li
Dongcheng Li
TRTengzhu Ren
Tengzhu Ren
HLHao Li
Hao Li
MHMingdi Huang
Mingdi Huang
JCJiaxin Chen
Jiaxin Chen
XZXiong Zhang
Xiong Zhang

10 March 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
WCWenwen Cheng
Wenwen Cheng
YYYan Yang
Yan Yang
YCYing Chen
Ying Chen
SSSharui Shan
Sharui Shan
CLChanghui Li
Changhui Li
XZXiong Zhang
Xiong Zhang
Background: This study aimed to evaluate the efficacy and tolerability of Anti-Seizure medication (ASM) treatment in patients with BECTS.Method: We searched PubMed, Cochrane Library, Embase, MEDLINE, Web of Science, China National Knowledge Infrastructure (CNKI), WANFANG DATA, and China Science and Technology Journal Database (VIP) between 1 Jan 1990, and 1 Sep 2021, for randomized controlled studies. Data on seizure freedom rate, rate of treatment withdrawal due to serious adverse events, rate of any adverse events and dropout, 50% remission rate, the proportion of patients whose EEG to be normalized, and improvement in cognitive function were extracted by two authors independently. The pooled data were meta-analyzed using a random effects model.Results: A total of 27 studies evaluating 9 ASMs were included, 19 of which were suitable for meta-analysis. Compared with sulthiame (STM), levetiracetam (LEV) was associated with a higher probability of treatment withdrawal due to serious adverse events [RR = 5.12, 95% CI (1.19, 22.01), I2 = 0.0%], experiencing any adverse events [RR = 5.12, 95% CI (1.19, 22.01)], and dropping out for any reason [RR = 3.17, 95% CI (1.36, 10.11)], while it did not affect the seizure freedom rate [RR = 0.90, 95% CI (0.75, 1.06)]. LEV significantly improved cognitive performance relative to carbamazepine (CBZ) but had no effect on the proportion of any adverse events [RR = 0.62, 95% CI (0.25, 1.59)] and EEG to be normalized [RR = 1.27, 95% CI (0.94, 1.71)]. There was no higher probability of a 50% remission rate when comparing valproic acid (VPA) to LEV [RR = 0.96, 95% CI (0.57, 1.61)] and oxcarbazepine (OXC) [RR = 0.61, 95% CI (0.31, 1.20)]. In addition, STM was related to a higher probability of EEG normalization than placebo [RR = 4.61, 95% CI (2.12, 10.01)]. The included single studies also provided some evidence for the efficacy and/or tolerability of other ASMs in BECTS, including topiramate, lamotrigine, clobazam, and clonazepam. The risk of bias of the included studies was frequently low or unclear.Conclusion: This study indicated some discrepancies in efficacy and tolerability among ASMs used in patients with BECTS. More randomized controlled trials (RCTs) comparing ASMs with larger populations are required to ascertain the optimum antiepileptic drug treatment to guide clinicians.

21 May 2025 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
SYShisheng Ye
Shisheng Ye
KFKaiyan Feng
Kaiyan Feng
GZGuofang Zeng
Guofang Zeng
JCJiaxin Cai
Jiaxin Cai
LLLijuan Liang
Lijuan Liang
XZXiong Zhang
Xiong Zhang
Introduction: Although white matter hyperintensities (WMH) are radiologically classified as deep WMH (DWMH) and periventricular WMH (PVWMH) based on spatial distribution, the distinct metabolic perturbations driving their pathogenesis remain incompletely characterized.Methods: This study integrated untargeted metabolomics with MRI phenotyping to delineate metabolic perturbations of WMH in arteriosclerotic cerebral small vessel disease (aCSVD) patients (n = 30) versus controls (n = 29). Plasma metabolic profiles were analyzed using UPLC-MS. Weighted gene correlation network analysis (WGCNA) evaluated associations between metabolite clusters and clinical traits, including DWMH volume, PVWMH volume and total WMH (TWMH) volume.Results: We identified 15, 16, and 16 key metabolites meeting both differential expression and WGCNA hub criteria for DWMH, PVWMH, and TWMH, respectively. Pathway Enrichment identified α-linolenic acid and linoleic acid metabolism as common pathway perturbed across both WMH categories. Key metabolites of the pathway, including docosahexaenoic acid (DHA) and stearidonic acid (SDA), demonstrated robust inverse associations with WMH volumes in confounder-adjusted linear regression models. Notably, both WMH categories share common metabolites, particularly polyunsaturated fatty acids (PUFA), while PVWMH-specific metabolites were primarily carnitine derivatives, and DWMH-specific metabolites were prostaglandin E2 and etodolac.Conclusion: These findings offer new insights into the metabolic mechanisms underlying DWMH and PVWMH in aCSVD. However, the cross-sectional nature of the study does not allow for causal conclusions. Future longitudinal studies are needed to validate the temporal relationships between metabolic perturbations and WMH progression.